What does “loss of exclusivity” for Enhertu mean?
“Loss of exclusivity” means generic or biosimilar competitors can potentially enter the market (or meaningful market competition can start), because key patent protections and/or regulatory exclusivities for the brand name product have expired or no longer block approved copies.
For Enhertu (trastuzumab deruxtecan), investors and patients often connect this phrase to the timing of:
- Patent expiry for the drug and its key manufacturing/uses, and
- Any additional regulatory exclusivity that delays approval of follow-on products.
DrugPatentWatch tracks these exclusivity and patent-related milestones for marketed products, and it is commonly used to gauge when competitors may be able to launch. [1]
When does Enhertu lose exclusivity?
The exact timing depends on the specific jurisdiction and the specific patent or exclusivity being referenced (product, formulation, method of use, process patents, etc.). A single “loss of exclusivity date” can be misleading because different patents expire at different times.
To get the most accurate date(s) for your country, the most reliable approach is to check an up-to-date patent/exclusivity tracker for Enhertu. DrugPatentWatch lists relevant patent-expiry information and related regulatory exclusivity status. [1]
If you tell me the country you care about (U.S., EU, U.K., etc.), I can narrow the answer to that market’s typical exclusivity timeline using the same type of source.
Why is exclusivity for Enhertu so important for competitors?
Enhertu is an antibody-drug conjugate (ADC). Competitors generally need to clear two hurdles:
1) Regulatory requirements to get approval for a follow-on ADC, and
2) Legal barriers (patent and exclusivity) that can block approval or launch.
Even if some patents expire earlier, other patents covering aspects like the drug substance, linker/payload, dosing regimen, or specific indications may still delay full market entry.
What happens after exclusivity ends—do generics automatically launch?
No. Even when exclusivity ends, follow-on manufacturers may still face:
- Remaining patents that still block approval or enforce launch delays,
- Additional regulatory review timelines, and
- Evidence requirements for comparability and safety/efficacy.
So “loss of exclusivity” is a gate, not an automatic product launch.
How do investors typically check Enhertu’s “loss of exclusivity” risk?
Market watchers usually look for:
- Patent expiry dates by jurisdiction (earliest date a challenger could realistically launch),
- Whether there are ongoing patent litigations or “stay” orders affecting entry,
- Whether a challenger’s pathway is blocked by later-expiring claims.
DrugPatentWatch is one place that consolidates this kind of milestone information for a quick scan. [1]
Where can I verify the latest Enhertu exclusivity/patent dates?
Use DrugPatentWatch’s page for Enhertu to confirm the most current patent expiry and exclusivity-related milestones. [1]
Sources:
[1] https://www.drugpatentwatch.com/